Figure 5. LY2801653 inhibits growth of tumor xenografts in nude mice.

A. Results from tumor xenograft experiments testing the efficacy of LY2801653 in inhibiting the growth of A549 or H1993 cell line tumors in nude mice. Oral gavage treatment with LY2801653 at 20 mg/kg/day reduced A549 and H1993 tumor growth significantly relative to vehicle control (p<0.05). B. Representative images of mice and tumors treated with LY2801653 and control. C. Immunohistochemical staining and evaluation. H&E histologic staining for necrosis and mitotic figures, CD31 for angiogenesis, Ki-67 antibody staining for cell proliferation, and caspase-3 for apoptosis were evaluated via immunohistochemistry. Bar graphs indicate quantification of 10 or 11 mice samples (n=10 or 11). Three random fields in each mouse sample were evaluated for mitotic figures and vessels (n=30 or 33). Error bars represent SEM. P-value between mean tumor volumes, the percentage of positive cells, or the numbers of mitotic figures and vessels of vehicle control and LY2801653 by two-tailed Student’s t test (*: p-value <0.05, **: p-value <0.01, ***: p-value <0.001, ****: p-value <0.0001).